First Time Loading...
N

Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707

Watchlist Manager
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
Watchlist
Price: 13.7 CNY 5.14% Market Closed
Updated: May 5, 2024

Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Net Income (Common) Peer Comparison

Comparables:
H
3692
600436
600276
000538
C
300765

Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
N
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
Net Income (Common)
¥1B
CAGR 3-Years
10%
CAGR 5-Years
19%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Net Income (Common)
¥3.3B
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Net Income (Common)
¥2.8B
CAGR 3-Years
21%
CAGR 5-Years
22%
CAGR 10-Years
21%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Net Income (Common)
¥4.2B
CAGR 3-Years
-10%
CAGR 5-Years
2%
CAGR 10-Years
13%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Net Income (Common)
¥4.1B
CAGR 3-Years
-9%
CAGR 5-Years
3%
CAGR 10-Years
6%
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Net Income (Common)
¥755.6m
CAGR 3-Years
36%
CAGR 5-Years
28%
CAGR 10-Years
N/A

See Also

What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Net Income (Common)?
Net Income (Common)
1B CNY

Based on the financial report for Sep 30, 2023, Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Net Income (Common) amounts to 1B CNY.

What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
19%

Over the last year, the Net Income (Common) growth was -9%. The average annual Net Income (Common) growth rates for Nanjing King-friend Biochemical Pharmaceutical Co Ltd have been 10% over the past three years , 19% over the past five years .